Safety risks and ethical governance of biomedical applications of synthetic biology

被引:1
|
作者
Ou, Yakun [1 ,2 ]
Guo, Shengjia [1 ]
机构
[1] Huazhong Univ Sci & Technol, Sch Marxism, Wuhan, Peoples R China
[2] Huazhong Univ Sci & Technol, Ctr Bioeth, Wuhan, Peoples R China
基金
美国国家科学基金会;
关键词
synthetic biology; participant safety; biosafety risks; biosecurity risks; ethical governance; public policy; GENE-THERAPY; TRIALS;
D O I
10.3389/fbioe.2023.1292029
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: In recent years, biomedicine has witnessed rapid advancements in applying synthetic biology. While these advancements have brought numerous benefits to patients, they have also given rise to a series of safety concerns.Methods: This article provides a succinct overview of the current research on synthetic biology's application in biomedicine and systematically analyzes the safety risks associated with this field. Based on this analysis, the article proposes fundamental principles for addressing these issues and presents practical recommendations for ethical governance.Results: This article contends that the primary safety risks associated with the application of synthetic biology in biomedicine include participant safety, biosafety risks, and biosecurity risks. In order to effectively address these risks, it is essential to adhere to the principles of human-centeredness, non-maleficence, sustainability, and reasonable risk control. Guided by these fundamental principles and taking into account China's specific circumstances, this article presents practical recommendations for ethical governance, which include strengthening ethical review, promoting the development and implementation of relevant policies, improving legal safeguards through top-level design, and enhancing technical capabilities for biocontainment.Conclusion: As an emerging field of scientific technology, synthetic biology presents numerous safety risks and challenges in its application within biomedicine. In order to address these risks and challenges, it is imperative that appropriate measures be implemented. From a Chinese perspective, the solutions we propose serve not only to advance the domestic development of synthetic biology but also to contribute to its global progress.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Microbial Governance - The Ethical Challenge of Synthetic Biology
    Chakraborty, Sweta
    Caplan, Arthur
    EUROPEAN JOURNAL OF RISK REGULATION, 2013, 4 (01) : 73 - 76
  • [2] Emerging biomedical applications of synthetic biology
    Weber, Wilfried
    Fussenegger, Martin
    NATURE REVIEWS GENETICS, 2012, 13 (01) : 21 - 35
  • [3] Emerging biomedical applications of synthetic biology
    Wilfried Weber
    Martin Fussenegger
    Nature Reviews Genetics, 2012, 13 : 21 - 35
  • [4] SYNTHETIC BIOLOGY programming cells for biomedical applications
    Hoerner, Maximilian
    Reischmann, Nadine
    Weber, Wilfried
    PERSPECTIVES IN BIOLOGY AND MEDICINE, 2012, 55 (04) : 490 - 499
  • [5] SYNTHETIC BIOLOGY programming cells for biomedical applications DISCUSSION
    Shoshan-Barmatz
    Weber
    Roth
    Armon
    PERSPECTIVES IN BIOLOGY AND MEDICINE, 2012, 55 (04) : 500 - 502
  • [6] Structural materials meet synthetic biology in biomedical applications
    Zhang, Xiaoxuan
    Fussenegger, Martin
    MATERIALS TODAY, 2024, 72 : 163 - 182
  • [7] Editorial: Advanced microfluidics for synthetic biology and/or biomedical applications
    Ren, Xiang
    Yu, Miao
    Kim, Inyoung
    Nam, Wonil
    Qin, Yuxiang
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2024, 12
  • [8] SYNTHETIC BIOLOGY: LEGAL, SOCIAL AND ETHICAL CHALLENGES TO ITS REGULATION AND GOVERNANCE
    Allan, Sonia
    Vickovich, Ilija
    MACQUARIE LAW JOURNAL, 2015, 15 : 1 - 3
  • [9] Engineering of optogenetic devices for biomedical applications in mammalian synthetic biology
    Guan, Ningzi
    Gao, Xianyun
    Ye, Haifeng
    Engineering Biology, 2022, 6 (2-3): : 35 - 49
  • [10] The Role of Protein Engineering in Biomedical Applications of Mammalian Synthetic Biology
    Bojar, Daniel
    Fussenegger, Martin
    SMALL, 2020, 16 (27)